A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: GlaxoSmithKline
This PHASE3 trial investigates Pulmonary Disease, Chronic Obstructive and is currently completed. GlaxoSmithKline leads this study, which shows 9 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Aug 2017 — Feb 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus C, Denmark , Arkhangelsk, Russia , Aschaffenburg, Germany , Bacau, Romania , Barnaul, Russia , Bellville, South Africa , Berlin, Germany , Bletterans, France , Boksburg, South Africa , Brăila, Romania and 71 more locations